Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Udenafil in Pulmonary Arterial Hypertension
NCT01553721Phase 2Completed
- Sponsor
- Dong-A ST
- Start
- Aug 2011
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing udenafil with placebo (2 arms). Primary endpoints: Pulmonary Vascular Resistance Index at 4 hours and 6-Minute Walk Distance at 16 weeks. Started Aug 2011; status: completed.
02
Drugs
udenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01553721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01553721.